Clinical Trials
7 trialsNCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT00027625 2018-06-27
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00025675 2018-06-26
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00016991 2013-06-20
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Duke University
Phase 2 Completed
NCT00238251 2012-06-05
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Phase 2 Completed
NCT00238797 2011-01-21
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
AstraZeneca
Phase 2 Completed